{
    "ticker": "INDP",
    "name": "Indaptus Therapeutics, Inc.",
    "description": "Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer treatment. Founded in 2016, Indaptus aims to harness the power of the immune system to fight cancer through its proprietary platform, which combines a unique approach to delivering therapeutic agents directly to tumor cells. The company's lead product candidate, INDP-001, is designed to activate the immune response and enhance the effectiveness of existing cancer therapies. Indaptus is dedicated to advancing its pipeline of candidates, which includes therapies for various solid tumors and hematological malignancies. With a team of experienced professionals in drug development and immunology, Indaptus is committed to improving patient outcomes through groundbreaking research and development. The company's mission is to bring hope to patients with cancer by providing novel treatment options that are both effective and well-tolerated. Indaptus is strategically positioned in the biotech space, leveraging cutting-edge science and technology to advance its therapeutic candidates toward clinical success.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2016",
    "website": "https://www.indaptustx.com",
    "ceo": "James P. O\u2019Brien",
    "social_media": {
        "twitter": "https://twitter.com/IndaptusTx",
        "linkedin": "https://www.linkedin.com/company/indaptus-therapeutics/"
    },
    "investor_relations": "https://ir.indaptustx.com",
    "key_executives": [
        {
            "name": "James P. O\u2019Brien",
            "position": "CEO"
        },
        {
            "name": "David D. R. H. H. B. Grinberg",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Immunotherapy",
            "products": [
                "INDP-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Indaptus Therapeutics, Inc. | Innovative Cancer Immunotherapies",
        "meta_description": "Explore Indaptus Therapeutics, Inc., a clinical-stage biotech company focused on developing novel immunotherapies for cancer treatment. Learn about our innovative pipeline and commitment to improving patient outcomes.",
        "keywords": [
            "Indaptus",
            "Cancer Immunotherapy",
            "Biotechnology",
            "Biopharmaceuticals",
            "INDP-001"
        ]
    },
    "faq": [
        {
            "question": "What does Indaptus Therapeutics focus on?",
            "answer": "Indaptus Therapeutics focuses on developing innovative immunotherapies for cancer treatment."
        },
        {
            "question": "Who is the CEO of Indaptus Therapeutics?",
            "answer": "James P. O\u2019Brien is the CEO of Indaptus Therapeutics, Inc."
        },
        {
            "question": "Where is Indaptus Therapeutics headquartered?",
            "answer": "Indaptus Therapeutics is headquartered in New York, New York, USA."
        },
        {
            "question": "What is Indaptus's lead product candidate?",
            "answer": "Indaptus's lead product candidate is INDP-001, designed to activate the immune response against tumors."
        },
        {
            "question": "When was Indaptus Therapeutics founded?",
            "answer": "Indaptus Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "NK",
        "CLVS",
        "ADAP",
        "XBI"
    ],
    "related_stocks": [
        "MRNA",
        "BMY",
        "AMGN",
        "GILD"
    ]
}